Moreover, a retrospective study conducted in the United States demonstrated that patients with a prior history of gastrointestinal disorders exhibited a significantly elevated risk of gastrointestinal adverse events when treated with GLP-1 RAs, corroborating the current study’s identification of concomitant gastrointestinal diseases as an independent risk factor (29). This evidence concerns the gene GLP1R and digestive system disorder.